| Taspoglutide |
|
| (CAS 275371-94-3) |
 |
| Description： |
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.
Two phase II trials reported it was effective and well tolerated.
Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide, sitagliptin, insulin glargine, and pioglitazone), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)
In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects.
As of May 2013 no new trials had been registered. |
| Product No. |
KT10080 |
| Product Name |
Taspoglutide |
| Synonyms |
BIM 51077;ITM 077;R 1583;RO 5073031;7-36-Glucagon-likepeptide I (human), 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide-; |
| Formal Name |
|
| CAS Number |
275371-94-3 |
| Molecular Formula |
C152H232N40O45 |
| Formula Weight |
3339.75 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
Leuprorelin Acetate
Lipopeptide Acetate
Liraglutide
Lixisenatide
Lysipressin Acetate
Matrixyl
Melanotan II
Nafarelin Acetate
Nesiritide Acetate
Octreotide
Octreotide acetate
Ornipressin Acetate
Vapreotide Acetate
Vapreotide acetate
Vasopressin Acetate
Ziconotide acetate
|
|
